Back to Search Start Over

OP0050 Gene polymorphisms of the glucocorticoid receptor and 11Β-hydroxysteroid dehydrogenase type 1 affect relevant clinical outcomes in anca associated vasculitis

Authors :
Abraham Rutgers
C. A. Stegeman
E.F.C. van Rossum
Jan-Stephan F. Sanders
Arno C Hessels
F.J.W. Koper
A. P. van Beek
Minke G. Huitema
Janneke Tuin
Source :
WEDNESDAY, 13 JUNE 2018.
Publication Year :
2018
Publisher :
BMJ Publishing Group Ltd and European League Against Rheumatism, 2018.

Abstract

Background High doses of exogenous glucocorticoids (e.g., prednisolone) are a standard part of treatment for ANCA-associated vasculitis.1 Efficacy and toxicity of glucocorticoid treatment differ widely between individuals.2 We hypothesised that this can be partly explained by genetic polymorphisms of the glucocorticoid receptor (GR) and 11β-hydroxysteroid dehydrogenase type 1 (HSD11B1) that influence glucocorticoid sensitivity. Objectives To investigate whether five haplotypes of the Glucocorticoid Receptor gene (NR3C1) and a single nucleotide polymorphism of 11β-hydroxysteroid dehydrogenase type 1 (HSD11B1) are associated with treatment efficacy and toxicity in ANCA associated vasculitis. Methods A total of 241 ANCA associated vasculitis patients were genotyped for five polymorphisms of the glucocorticoid receptor gene and one polymorphism of the HSD11B1 gene. Glucocorticoid receptor gene haplotypes were predicted based on genotyping results. Relapse free survival, mortality, renal survival, metabolic adverse events and infections were compared between carriers and non-carriers of glucocorticoid receptor haplotypes and the HSD11B1 genotype. Results Carriers of the ER22/23EK haplotype of the glucocorticoid receptor had a significantly higher risk of 10 year mortality (Hazard Ratio (HR) 3.0, 95% confidence interval, CI: 1.2 to 7.3), more frequently required plasmapheresis treatment (p=0.04) and had a higher risk of developing end-stage renal disease (HR 7.4, 95% CI: 1.9 to 28.7). Carriers of a minor variant of HSD11B1 more frequently experienced relapse (HR 2.5, 95% CI: 1.5 to 4.1), except if they also carried the BclI haplotype of the glucocorticoid receptor. Homozygous carriers of the BclI haplotype had a higher risk of developing hypertension (HR 2.7, 95% CI: 1.2 to 5.7) and dyslipidemia (HR 4.1, 95% CI: 1.8 to 9.6). Occurrence of infections neither differed between GR haplotypes, nor between HSD11B1 genotypes. Conclusions The ER22/23EK and BclI haplotype of the glucocorticoid receptor and a polymorphism of the gene for HSD11B1 are associated with clinically relevant inflammatory and metabolic outcomes in ANCA associated vasculitis. References [1] Yates M, Watts RA, Bajema IM, Cid MC, Crestani B, Hauser T, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis2016Sep;75(9):1583–1594. [2] Quax RA, Manenschijn L, Koper JW, Hazes JM, Lamberts SW, van Rossum EF, et al. Glucocorticoid sensitivity in health and disease. Nat Rev Endocrinol2013Nov;9(11):670–686. Disclosure of Interest None declared

Details

Database :
OpenAIRE
Journal :
WEDNESDAY, 13 JUNE 2018
Accession number :
edsair.doi...........22c157a6e3d13440c3e5e64be3dbfbbc
Full Text :
https://doi.org/10.1136/annrheumdis-2018-eular.1047